The bioresorbable vascular scaffold (BRS) technology constitutes the new revolution of the coronary artery disease interventional treatment. Currently, three distinct types of BRSs are available but only one, the Absorb BVS, was on the market in 2013 when the Regional Commission for Medical Devices and the Cardiology and Cardiac Surgery Commission of the Emilia-Romagna Region drew up a technical and scientific essay to provide guidance for the introduction of BRS in public and affiliated health facilities. Five preferential indications were given for use: long coronary lesions (>28 mm), ostial lesions (left main stem excluded), complete revascularization in patients aged <50 years, diffuse disease (>40 mm) or involving the mid/distal left anterior descending (LAD) branch in patients <70 years, spontaneous coronary artery dissection.
[Bioresorbable vascular scaffolds: clinical experience of the Emilia-Romagna Region, Italy] / Menozzi, Alberto; Campo, Gianluca Calogero; Guiducci, Vincenzo; Dall'Ara, Gianni; Santarelli, Andrea; Sbarzaglia, Paolo; Balducelli, Marco; Magnavacchi, Paolo; Sgura, Fabio; Losi, Luciano; Vignali, Luigi; Casella, Gianni; Steffanon, Luigi; Tarantino, Fabio; Saia, Francesco. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - ELETTRONICO. - 18:2 Suppl 1(2017), pp. 9S-18S-18S. [10.1714/2657.27243]
[Bioresorbable vascular scaffolds: clinical experience of the Emilia-Romagna Region, Italy]
Dall'Ara, Gianni;Steffanon, Luigi;Tarantino, Fabio;Saia, Francesco
2017
Abstract
The bioresorbable vascular scaffold (BRS) technology constitutes the new revolution of the coronary artery disease interventional treatment. Currently, three distinct types of BRSs are available but only one, the Absorb BVS, was on the market in 2013 when the Regional Commission for Medical Devices and the Cardiology and Cardiac Surgery Commission of the Emilia-Romagna Region drew up a technical and scientific essay to provide guidance for the introduction of BRS in public and affiliated health facilities. Five preferential indications were given for use: long coronary lesions (>28 mm), ostial lesions (left main stem excluded), complete revascularization in patients aged <50 years, diffuse disease (>40 mm) or involving the mid/distal left anterior descending (LAD) branch in patients <70 years, spontaneous coronary artery dissection.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
